[{"orgOrder":0,"company":"Captor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Captor Therapeutics Presents Compelling In Vivo Proof-of-Concept Data from CT-01 Program in Hepatocellular Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"POLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Captor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Captor Therapeutics Announces Molecular Targets of CT-01 Program Developing TPD Therapy for Hepatocellular Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"POLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Captor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Captor Therapeutics Nominates the Molecular Glue CPT-6281 as Drug Candidate to Enter CTA\/IND-Enabling Studies for the Treatment of Hepatocellular Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"POLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Captor Therapeutics","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","amount":"$204.1 million","upfrontCash":"Undisclosed","newsHeadline":"Ono Pharmaceutical and Captor Therapeutics Announce Drug Discovery Collaboration to Develop Small Molecule Protein Degraders for the Treatment of Neurodegenerative Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"POLAND","productType":"Small molecule","productStatus":"Undisclosed","date":"November 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform"}]
Find Clinical Drug Pipeline Developments & Deals by Captor Therapeutics
TPD is an approach using carefully designed small molecule drugs that can divert the body’s natural process for degrading proteins to eliminate specifically targeted disease-causing proteins.
CPT-6281 as drug candidate for the CT-01 project, which will initially focus on the clinical development of the asset as a TPD treatment against hepatocellular carcinoma (HCC).
Compelling in-vitro and in-vivo preclinical data demonstrate that CT-01 candidate compounds induce degradation of Eukaryotic peptide chain release factor GTP-binding subunit, and another undisclosed neo-substrate with essential function in tumorigenesis.
Strong and comparable efficacy was demonstrated with CT-01 candidate, also confirming the potent antitumor activity in a liver cancer mouse xenograft model and no treatment-related toxicity was observed.